Amneal Pharmaceuticals, Inc. (AMRX) Stock

Amneal Pharmaceuticals, Inc. (AMRX) is a Healthcare stock trading at $17.91 (as of 2026-08-21), with a market capitalization of $5.71B and a trailing P/E of 36.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products across multiple dosage forms and therapeutic areas. It operates through Generics, Specialty, and AvKARE segments, including branded products and specialty therapies, and AvKARE’s supply of pharmaceuticals and related medical products to government and defense and veterans’ agencies.

Understand Amneal Pharmaceuticals, Inc.: how it makes money

Amneal Pharmaceuticals develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products, generating revenue from sales across its Generics, Specialty, and AvKARE segments.

Amneal’s profit model is primarily driven by product-mix across three commercial engines, with broad-based generic offerings across many dosage forms and therapeutic categories, plus a smaller specialty commercial and distribution footprint.

Revenue by segment (latest quarter)
Generics	$0.4B
Specialty	$0.1B
AvKARE	$0.2B

Business quality (Weak): Good overall segment visibility (Generics, Specialty, AvKARE are stated), but provided segment revenue detail is clearer for some branded or labeled components (for example, OutCare) than for every official segment name.

Valuation: At 44× earnings, AMRX trades 160% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

Diversified generic product set: The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Meaningful contribution from affordable medicines: In the latest quarter, Affordable Medicines segment revenue is 0.44 USD_B, indicating a large share of the operating activity is tied to the affordable medicines business.

Bear case

Specialty is smaller in the provided operating picture: Specialty revenue is 0.13 USD_B versus Affordable Medicines segment revenue of 0.44 USD_B, so changes in specialty performance may have limited impact relative to the affordable medicines engine.
Product-level contribution appears concentrated and some named products show no revenue in the provided data: Several named products and categories listed in the operating candidates show 0.0 USD_B revenue (for example, Brachia and Crexon), which can indicate limited near-term contribution from those specific items.

Valuation — source: SEC EDGAR (first-party)
Price	$17.91
Market Cap	$5.71B
P/E Ratio	36.3
EV / EBITDA	17.9
Price / Book	173.02
Price / Sales	1.83
FCF Yield	2.2%
DCF Value (model)	$20.79
DCF Upside vs Price	16.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$3.02B
Net Margin	2.4%
Revenue Growth (YoY)	9.9%
EPS Growth (YoY)	157.1%
FCF Growth (YoY)	-185.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.21 (grey)
Piotroski F-Score	7/9 (strong)

Valuation vs Sector & Industry
Stock P/E	36.3
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2
vs Sector	67.0%
vs Industry	111.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($304.77M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Chirag K. Patel
Employees	8,300
Country	US
IPO Date	2018-05-07

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.